Provenienza dei contatti di primo grado di Barbara Dalton
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Levicept Ltd.
Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom.
7
| Holding Company | Pharmaceuticals: Generic | 7 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Barbara Dalton tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Atlantic Healthcare Plc
Atlantic Healthcare Plc Pharmaceuticals: MajorHealth Technology Atlantic Healthcare Plc operates as holding company with interest in pharmaceutical. Its products include Alicaforsen Enema, an anti-inflammatory intercellular adhesion molecule inhibitor that acts by inhibiting a key protein in the inflammation process. The firm offers its product for the treatment of pouchitis and ulcerative colitis. The company was founded by Toby Wilson Waterworth and Fiona Mary Wilson Waterworth in 2006 and is headquartered in Saffron Walden, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Sequenta, Inc.
Sequenta, Inc. BiotechnologyHealth Technology Sequenta, Inc. operates as a biotech company which discovers and develops clinical diagnostics based on immune system status. It develops molecular diagnostic assays based on a sequencing approach to the profiling of T and B cell receptor repertoires. The firm also provides sequencing-based test for minimal residual disease for leukemia and lymphoma. The company was founded by Thomas D. Willis and Malek Faham in 2007 and is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member | |
ZYLA LIFE SCIENCES | Pharmaceuticals: Major | Director/Board Member | |
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
GENMAB A/S | Pharmaceuticals: Major | Director/Board Member | |
The University of Liverpool
The University of Liverpool Other Consumer ServicesConsumer Services The University of Liverpool operates as a university. It offers post graduate research, foundation courses, continuing and professional development, online study, and doctoral college. The company was founded in 1881 and is headquartered in Liverpool, the United Kingdom. | College/University | Doctorate Degree | |
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering, Inc. (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor | |
Chroma Therapeutics Ltd.
Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Chairman | |
ADDEX THERAPEUTICS LTD | Pharmaceuticals: Major | Director/Board Member | |
FlowCardia, Inc.
FlowCardia, Inc. Medical SpecialtiesHealth Technology FlowCardia, Inc. designs, develops and manufactures endovascular devices. It offers flowmate Injector to optimize the performance of crosser cto recanalization and crosser catheter, a minimally-invasive endovascular device. The firm also provides portfolio of catheter-based technologies to facilitate guidewire crossing of totally occluded coronary and peripheral arteries. The company was founded by Henry Nita and Erik T. Engelson in 2001 and is headquartered in Sunnyvale, CA. | Medical Specialties | Director/Board Member | |
University of Leiden | College/University | Undergraduate Degree | |
Henley Management College | College/University | Masters Business Admin | |
PROTALIX BIOTHERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman | |
MOLECULAR PARTNERS AG | Biotechnology | Director/Board Member Director/Board Member | |
Gilde Healthcare Partners BV
Gilde Healthcare Partners BV Investment ManagersFinance Gilde Healthcare Partners BV is a Private Equity/Venture Capital firm, a subsidiary of Gilde Healthcare Holding BV founded in 1999 by Pieter van der Meer and Edwin William de Graaf. Gilde Healthcare Partners BV is headquartered in Utrecht with additional office in Cambridge. | Investment Managers | Private Equity Investor | |
Index Ventures (UK) LLP | Investment Managers | Private Equity Investor Private Equity Investor | |
Moximed, Inc.
Moximed, Inc. Medical SpecialtiesHealth Technology Moximed, Inc. develops minimally invasive, joint sparing solutions for patients with knee osteoarthritis. Its Osteoarthritis treatment can minimize joint pain, restore normal activity levels, and slow down disease progression. The company was founded by Anton G. Clifford in 2006 and is headquartered in Hayward, CA. | Medical Specialties | Director/Board Member | |
ViiV Healthcare Ltd.
ViiV Healthcare Ltd. Pharmaceuticals: MajorHealth Technology ViiV Healthcare Ltd. manufactures and distributes pharmaceutical products. Its medicine include Triumeq, Tivicay, Selzentry, Celesentri, Epzicom, Kivexa, Ziagen, Trizivir, Combivir, Retrovir AZT, Lexiva, Telzir, Viracept and Rescriptor. The company was founded in 2009 and is headquartered in Brentford, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
STAT-Dx Life SL
STAT-Dx Life SL Medical SpecialtiesHealth Technology STAT-Dx Life SL focuses on the development, manufacturing and commercialization of diagnostic solutions for fast and accurate diagnostic results of infectious diseases and critical care. It solution offers DiagCORE Cartridge, for sample and analyzation of cell material, nucleic acid purification, amplification and hybridization process. The company was founded by Jordi Cabrrera Fabra and Rafael Bru Gibert in 2010 and is headquartered in Barcelona, Spain. | Medical Specialties | Director/Board Member | |
Xenikos BV
Xenikos BV Medical SpecialtiesHealth Technology Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands. | Medical Specialties | Director/Board Member | |
Egalet A/S
Egalet A/S Pharmaceuticals: MajorHealth Technology Egalet A/S operates as a specialty pharmaceuticals company. It develops opioid formulations for pain management based on abuse deterrent prolonged release erosion matrix technology in Denmark. The company develops prolonged and delayed release therapeutics for chronic pain management, including Parvulet, a delivery platform for facilitating dispensing of oral doses to pediatric and geriatric patient segments; and Egalet morphine. The company was founded by Jan Quistgaard in 1995 and is headquartered in Vaerloese, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
MINERVA NEUROSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member | |
Calypso Biotech SA
Calypso Biotech SA Pharmaceuticals: MajorHealth Technology Calypso Biotech SA operates as a innovative biopharmaceutical company for gastrointestinal immunological disorders. The company was founded by Alain Vicari and Yolande Chvatchko in 2013 and is headquartered in Plan-les-Ouates, Germany. | Pharmaceuticals: Major | Director/Board Member | |
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Investment Managers | Founder Founder Private Equity Investor | |
Capella Bioscience Ltd.
Capella Bioscience Ltd. Pharmaceuticals: MajorHealth Technology Capella Bioscience Ltd. develops medicines based on monoclonal antibodies to the next generation therapeutic targets in oncology and autoimmune disease. The company was founded by Steve Holmes in 2014 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Inhibitaxin Ltd.
Inhibitaxin Ltd. BiotechnologyHealth Technology Inhibitaxin Ltd. engages in research and development on biotechnology. The company was founded by Simon Lempriere Westbrook and Kevin S. Johnson in 2013 and is headquartered in Kent, the United Kingodm. | Biotechnology | Founder Founder | |
UltraHuman Ltd.
UltraHuman Ltd. Miscellaneous Commercial ServicesCommercial Services UltraHuman Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Sandwich, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Critical Pressure Ltd.
Critical Pressure Ltd. Pharmaceuticals: MajorHealth Technology Critical Pressure Ltd. engages in research and experimental development on biotechnology. The firm develops products to treat vascular dysfunction and shock. The company is headquartered in Babraham, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
SpliceBio SL
SpliceBio SL BiotechnologyHealth Technology SpliceBio SL is a genetic medicines company based in Barcelona, Spain. The Spanish company harnesses its proprietary protein splicing platform to develop the next generation of gene therapies. SpliceBio's platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by -associated virus (AAV) vectors. The company's lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio's platform is based on technology developed in the Muir lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. The company was founded by Dominguez Silvia Frutos, Miquel Vila-Perelló, and Miquel Vila-Perelló has been the CEO since incorporation. | Biotechnology | Director/Board Member | |
Sitryx Therapeutics Ltd.
Sitryx Therapeutics Ltd. Medical SpecialtiesHealth Technology Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom. | Medical Specialties | Founder | |
Calypso Biotech BV
Calypso Biotech BV BiotechnologyHealth Technology Calypso Biotech BV operates as immunotherapy biotech company. It develops monoclonal antibodies for the treatment of immune pathologies with large unmet medical needs. The company was founded by Alain Vicari and Yolande Chvatchko in 2013 and is headquartered in Amsterdam, the Netherlands. | Biotechnology | Director/Board Member | |
Ochre Bio Ltd.
Ochre Bio Ltd. Pharmaceuticals: MajorHealth Technology Ochre Bio Ltd. is a biotechnology company based in Headington, UK. Ochre Bio is focused on developing RNA medicines for chronic liver diseases. The British company uses deep phenotyping, precision RNA medicine, and testing in live human donor livers to develop therapies for important liver health challenges. The company's goal is to develop therapies that increase donor liver supply and reduce cirrhosis complications. The company was founded by Quin Wills and the CEO is Jack O'Meara. | Pharmaceuticals: Major | Chairman | |
Rivus Pharmaceuticals, Inc.
Rivus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rivus Pharmaceuticals, Inc. is a company dedicated to improving metabolic health by advancing a new class of medicines called controlled metabolic accelerators (CMAs). The company is based in Charlottesville, VA. Jayson Donald Alexander Dallas has been the CEO of the company since 2021. The company is a leader in mitochondrial biology and is developing a new class of medicines to address a primary driver of cardio-metabolic disease: obesity. Rivus' lead CMA is the investigational small molecule HU6 in development to treat obesity and associated metabolic diseases, including heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes. | Pharmaceuticals: Major | Director/Board Member | |
Orexia Therapeutics Ltd.
Orexia Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Orexia Ltd. develop orally administered orexin positive modulators for the treatment of neurological diseases. The company was founded on October 5, 2018 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Synox Therapeutics Ltd.
Synox Therapeutics Ltd. BiotechnologyHealth Technology Synox Therapeutics Ltd. a clinical stage biopharmaceutical company. The company is headquartered in Dublin, Ireland. | Biotechnology | Director/Board Member | |
Noema Pharma AG
Noema Pharma AG BiotechnologyHealth Technology Noema Pharma AG is a biotechnology company, which engages in the development of orphan neurological disorder therapies. It focuses on understanding and meeting patient needs using novel therapies. The company was founded by Luigi Costa and George Garibaldi and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member | |
CENTESSA PHARMACEUTICALS PLC | Pharmaceuticals: Major | Chairman | |
SDS Therapeutics Ltd.
SDS Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services SDS Therapeutics Ltd. is a British biotechnology company founded in 2020 that provides research and development services. The company is based in Cambridge, UK. | Miscellaneous Commercial Services | Director/Board Member | |
Immunocore Ltd.
Immunocore Ltd. Pharmaceuticals: MajorHealth Technology Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal. | Pharmaceuticals: Major | Chief Executive Officer | |
Tessellate Bio BV
Tessellate Bio BV BiotechnologyHealth Technology Tessellate Bio BV is a Dutch preclinical stage biotechnology company that focuses on discovering and developing precision oncology medicines. The company is based in Naarden, the Netherlands. The company's mission is to turn cancer patients into cancer survivors by targeting unexplored or difficult to drug pathways beyond HRD. The company is also developing companion diagnostics, including a potentially diagnostic to detect ALT positive cancers. Led by an experienced team of drug hunters, Tessellate Bio is building a pipeline of first-in-class medicines based on cutting-edge research. The company was founded by Hilda A. Pickett and the CEO is Andree Blaukat. | Biotechnology | Director/Board Member | |
Pfizer Holdings International Luxembourg (PHIL) SARL
Pfizer Holdings International Luxembourg (PHIL) SARL Financial ConglomeratesFinance Part of Pfizer Inc., Pfizer Holdings International Luxembourg (PHIL) SARL is an investment holding company. The company is based in Luxembourg, Luxembourg. | Financial Conglomerates | Corporate Officer/Principal |
Statistiche
Distribuzione geografica
Regno Unito | 21 |
Stati Uniti | 13 |
Paesi Bassi | 7 |
Svizzera | 5 |
Danimarca | 3 |
Settori
Health Technology | 39 |
Finance | 6 |
Commercial Services | 5 |
Consumer Services | 4 |
Posizioni
Director/Board Member | 121 |
Chief Executive Officer | 18 |
Corporate Officer/Principal | 15 |
Chairman | 14 |
Independent Dir/Board Member | 11 |
Contatti più connessi
Insiders | |
---|---|
Raj Bhikhu Parekh | 50 |
Francesco de Rubertis | 36 |
Eliot Forster | 35 |
Kevin Johnson | 22 |
Paul-Peter Tak | 15 |
Arthur Franken | 11 |
Simon Westbrook | 3 |
- Borsa valori
- Insiders
- Barbara Dalton
- Connessioni Società